학술논문
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.
Document Type
Letter to the Editor
Author
Source
Subject
*ALEMTUZUMAB
*T-cell lymphoma
*INTERLEUKIN-15
*SEZARY syndrome
*REGULATORY T cells
*ANTIBODY-dependent cell cytotoxicity
*KILLER cells
*CUTANEOUS T-cell lymphoma
*
*
*
*
*
*
*
Language
ISSN
1042-8194
Abstract
A phase 1 study was conducted to investigate the combination of interleukin-15 (IL-15) and avelumab in patients with relapsed or refractory T-cell lymphoma. IL-15 is known to stimulate NK and T-cell functions, and previous studies have shown that it can enhance the activity of anti-tumor monoclonal antibodies. Avelumab is an anti-PDL1 antibody that functions as an immune checkpoint inhibitor. The study enrolled eight patients, and although the maximum tolerated dose was not established due to early closure, two patients with PTCL-NOS had a partial response and two had stable disease. The results of this study can inform ongoing efforts to improve immunotherapy for T-cell lymphomas. [Extracted from the article]